Clinical trials: Gefitinib
Non-Small-Cell Lung Carcinoma
Iressa Versus Docetaxel (Taxotere)
The purpose of this study is to compare the effects of ZD1839 or docetaxel in patients with advanced non-small cell lung cancer (NSCLC) that has recurred or progressed after receiving prior treatment with platinum-based…
- Trial name
- NCT00076388
- Testing
- Gefitinib, Docetaxel
- Where
- 162 sites in United States, Argentina and 23 more
- Volunteers
- 1,440 people
- Sponsor
- AstraZeneca
Lung Cancer
Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer
Because of the demonstrated single agent activity and excellent tolerability in patients with refractory non-small cell lung cancer, ZD1839 may be of benefit in the first-line treatment of patients with advanced non-small cell…
- Trial name
- NCT00193336
- Testing
- ZD1839
- Volunteers
- 60 people
- Sponsor
- SCRI Development Innovations, LLC
Esophageal Cancer
Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal Cancer
Elderly patients with esophageal cancer will receive thoracic radiation therapy 54-60Gy over 30 fractions, and concurrent with Gefitinib.
- Trial name
- NCT01291823
- Testing
- gefitinib, Thoracic radiotherapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer
A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer
This is a Phase II, randomised, double-blind, placebo-controlled study. Subjects with histologically-confirmed oestrogen receptor negative (ER-), progesterone receptor negative (PgR-) primary breast cancer breast cancer will be…
- Trial name
- NCT00252811
- Testing
- Gefitinib
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Squamous Cell Carcinoma of the Head and Neck
Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)
This study is to compare ZD1839 (250mg and 500mg) versus methotrexate in head and neck cancer in terms of overall survival.
- Trial name
- NCT00206219
- Testing
- Gefitinib, methotrexate
- Where
- 109 sites in United States, Argentina and 23 more
- Volunteers
- 477 people
- Sponsor
- AstraZeneca
Metastatic Colorectal Cancer
Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer
The aim of the study is to determine if Iressa added to chemotherapy with Irinotecan, 5Fluorouracil and Leucovorin can prolong the period of time without any disease worsening (Time to Progression) in patients with metastatic…
- Trial name
- NCT00233623
- Testing
- Iressa (Gefitinib), Irinotecan, 5Fluorouracil
- Where
- 13 sites in Italy
- Volunteers
- 190 people
- Sponsor
- AstraZeneca
Head and Neck Cancer, Carcinoma, Squamous Cell
Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck
The aim of the study is to determine if Iressa added to radiotherapy is effective and safe in shrinking tumour dimensions.
- Trial name
- NCT00233636
- Testing
- Iressa (Gefitinib), Radiotherapy
- Where
- 6 sites in Italy
- Volunteers
- 28 people
- Sponsor
- AstraZeneca
Breast Cancer
Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer
The aim of the study is to estimate the effect of preoperative gefitinib on the complete pathological response rate in primary estrogen receptor negative breast cancer at the time of surgery.
- Trial name
- NCT00239343
- Testing
- gefitinib
- Where
- 8 sites in Denmark, Norway and 1 more
- Volunteers
- 160 people
- Sponsor
- AstraZeneca
Head and Neck Cancer
ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer
The primary objective of the study is to evaluate the activity of the combination ZD1839, docetaxel and cisplatin in subjects with recurrent and/or metastatic head and neck cancer by estimating the objective response rate…
- Trial name
- NCT00242762
- Testing
- ZD1839 (IRESSA™), Docetaxel, Cisplatin
- Where
- 4 sites in Spain
- Volunteers
- 36 people
- Sponsor
- AstraZeneca
Non-small-cell Lung Cancer
A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer
The purpose of this study is to characterize the safety profile of ZD1839 in combination with Palliative thoracic Radiotherapy in patients with non-small cell lung cancer
- Trial name
- NCT00255489
- Testing
- Gefitinib, palliative thoracic radiotherapy
- Where
- 2 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- AstraZeneca
Locally Advanced Prostate Cancer
Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer
The purpose of this study is to determine if the addition of ZD1839 Iressa™ to standard treatment with Casodex® (bicalutamide) for locally advanced prostate cancer can detect a difference in the rate of decrease of prostate…
- Trial name
- NCT00319787
- Testing
- Iressa
- Where
- 3 sites in Norway
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
Glioblastoma
A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme
The purpose of the study is to determine the efficacy of gefitinib (IressaTM) in combination with radiotherapy on patients with glioblastoma multiforme.
- Trial name
- NCT00238797
- Testing
- Gefitinib
- Where
- 3 sites in Sweden
- Volunteers
- 36 people
- Sponsor
- AstraZeneca
Lung Cancer
First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker
The investigators will conduct the randomized trial to determine the role of Gefitinib monotherapy as first-line setting in adenocarcinoma patients with no history of smoking, as compared with the standard combination…
- Trial name
- NCT00455936
- Testing
- Gefitinib, chemotherapy
- Where
- 3 sites in South Korea
- Volunteers
- 315 people
- Sponsor
- National Cancer Center, Korea
Head and Neck Cancer
Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer
To evaluate the feasibility and safety of (cohort 1) postoperative standard fractionation radiotherapy plus Iressa and of (cohort 2) hyperfractionated radiotherapy plus cisplatin and Iressa
- Trial name
- IRESSA&H&N (NCT00681967)
- Testing
- Gefitinib
- Where
- 2 sites in Switzerland
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers
The purpose of this study is to compare the efficacy and safety of chemotherapy followed sequentially by gefitinib versus chemotherapy alone in the first line treatment of non-small cell lung cancer (NSCLC).
- Trial name
- NCT00409006
- Testing
- Pemetrexed, Cisplatin, Gefitinib
- Where
- 7 sites in China, South Korea and 1 more
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Toxicity, Non-small Cell Lung Cancer
Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients
The purpose of this study is to examine the efficacy and safety of gefitinib combinated with Pemetrexed/Cisplatin in advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT01192243
- Testing
- Gefitinib, Pemetrexed, Cisplatin or carboplatin
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Fudan University
Ovarian Cancer, Cancer of the Fallopian Tube
A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy
Although initially responsive to cytoreductive surgery and platinum- and/or taxane-based chemotherapy, a majority of patients with epithelial ovarian cancer, cancer of the fallopian tube or the peritoneum will eventually relapse.
- Conditions
- Ovarian Cancer, Cancer of the Fallopian Tube, Peritoneal Cancer
- Trial name
- NCT00189358
- Testing
- ZD1839, tamoxifen
- Where
- Germany
- Sponsor
- AGO Study Group
Non-small Cell Lung Cancer
Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)
RATIONALE: Radiation therapy to the brain may be effective in preventing brain metastases in patients with advanced non-small cell lung cancer.
- Trial name
- NCT01158170
- Testing
- Prophylactic cranial irradiation, Erlotinib /Gefitinib
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Zhejiang Cancer Hospital
Pulmonary Cancer
First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation
The purpose of this study is to evaluate the overall objective tumor response rate (ORR) of Gefitinib.
- Trial name
- NCT00344773
- Testing
- Gefitinib
- Where
- 2 sites in South Korea
- Volunteers
- 46 people
- Sponsor
- AstraZeneca
Head and Neck Cancer
Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer
Although gefitinib has been combined successfully with various chemotherapeutic regimens with minimal increase in overall toxicity, experience with concurrent radiation therapy is limited.
- Trial name
- NCT00193284
- Testing
- Gefitinib, Docetaxel, Carboplatin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- SCRI Development Innovations, LLC